The introduction of anti-TNFα drugs into the treatment of RP, ankylosing spondylitis, and other autoimmune diseases has revolutionized the management of patients with active diseases that resist conventional therapy. The gene discussed is TNF; the disease is retinitis pigmentosa 1.